Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

11.22
Delayed Data
As of 3:59pm ET
 +0.86 / +8.30%
Today’s Change
3.80
Today|||52-Week Range
11.29
+29.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$725.7M

Company Description

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. Its products are therapeutic agents, which are designed to target cancer and imaging agents, which enables clinicians and patients to visualize and manage diseases. The company was founded by Paul J. Maddon in 1986 and is headquartered in Tarrytown, NY.

Contact Information

Progenics Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591
P:(914) 789-2800
Investor Relations:

Employees

Shareholders

Mutual fund holders44.38%
Other institutional39.78%
Individual stakeholders12.37%

Top Executives

Mark Robert BakerChief Executive Officer & Director
Meryl J. LongvalVice President-Operations
Patrick FabbioChief Financial Officer & Senior Vice President
Thomas StrackVice President-Clinical Affairs
Vivien WongVice President-Product Development